Metagenomi Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
MGX$0.70-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| BALANCE—December 31, 2025 | 37,620,668 | $4 | $469,202 | $260 | $(310,870) | $158,596 |
| Vesting of restricted stock units | 27,081 | — | — | — | — | — |
| Forfeiture of unvested common stock | (692) | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,552 | — | — | 2,552 |
| Other comprehensive loss | — | — | — | (304) | — | (304) |
| Net loss | — | — | — | — | (23,059) | (23,059) |
| BALANCE—March 31, 2026 | 37,647,057 | 4 | 471,754 | (44) | (333,929) | 137,785 |
| Vesting of restricted stock units | 77,543 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan (ESPP) | 63,867 | — | 74 | — | — | 74 |
| Forfeiture of unvested common stock | (11,362) | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,268 | — | — | 2,268 |
| Other comprehensive loss | — | — | — | (78) | — | (78) |
| Net loss | — | — | — | — | (27,482) | (27,482) |
| BALANCE—June 30, 2026 | 37,777,105 | $4 | $474,096 | $(122) | $(361,411) | $112,567 |
| BALANCE—December 31, 2024 | 37,418,470 | $4 | $457,146 | $709 | $(223,002) | $234,857 |
|---|---|---|---|---|---|---|
| Vesting of restricted stock units | 11,371 | — | — | — | — | — |
| Forfeiture of unvested common stock | (47,363) | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,928 | — | — | 2,928 |
| Other comprehensive loss | — | — | — | (88) | — | (88) |
| Net loss | — | — | — | — | (25,039) | (25,039) |
| BALANCE—March 31, 2025 | 37,382,478 | 4 | 460,074 | 621 | (248,041) | 212,658 |
| Vesting of restricted stock units | 76,928 | — | — | — | — | — |
| Issuance of common stock under ESPP | 75,338 | — | 109 | — | — | 109 |
| Forfeiture of unvested common stock | (1,608) | — | — | — | — | — |
| Stock-based compensation expense | — | — | 3,221 | — | — | 3,221 |
| Other comprehensive loss | — | — | — | (249) | — | (249) |
| Net loss | — | — | — | — | (19,908) | (19,908) |
| BALANCE—June 30, 2025 | 37,533,136 | $4 | $463,404 | $372 | $(267,949) | $195,831 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.